文献速递炎症性肠病

新发儿童克罗恩病中治疗应答比诊断时疾病严重程度更能预测早期复发

Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2018-11-18

GROWTH CD前瞻性起始队列纳入282例新发儿童克罗恩病,178例(63.6%)在第12周达到无激素缓解。第12周PCDAI>5、CRP>20 mg/L和粪钙卫蛋白>400 µg/g与复发风险增加相关,基于第12周指标的预测模型灵敏度43%、特异度92%。早期复发与随访期并发症风险更高相关。

要点

  • 第12周PCDAI>5、CRP>20 mg/L、粪钙卫蛋白>400 µg/g与复发风险增加相关。
  • 第12周疾病活动或炎症指标预测复发优于诊断时数据。
  • 复发患者并发症发生率为29%(22/76),无复发患者为9.7%(20/206)。

核心结论

  • 早期复发与随访期并发症风险更高相关,基于第12周疾病活动或炎症的复发预测优于使用诊断时数据。

研究设计与样本

  • GROWTH CD前瞻性起始队列,纳入282例新发儿童克罗恩病患者,基线及第12周评估28个二分和连续变量,随访至78周。

主要发现

  • 282例中178例(63.6%)在第12周达到无激素缓解。
  • 复发患者中22/76(29%)出现疾病并发症,无复发患者中20/206(9.7%)出现并发症(P=0.01)。
  • 多变量分析显示第12周PCDAI>5(P=0.02)、CRP>20 mg/L(P=0.02)、粪钙卫蛋白>400 µg/g(P=0.03)作为最佳截断值与复发风险增加相关,而诊断时年龄/性别变量无预测作用。
  • 基于性别、年龄、第12周PCDAI、钙卫蛋白和CRP的缓解患者预测模型对复发的灵敏度43%、特异度92%、PPV 78%、NPV 71%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paediatric Crohn's disease is characteried by frequently relapsing disease which may lead to hospitalisations and complications. AIM: To develop predictive models for early relapse following first remission. METHODS: The GROWTH CD prospective inception cohort was designed to predict risk for early disease relapse and poor outcomes. Newly diagnosed children underwent endoscopies and imaging. They were phenotyped and followed at scheduled visits through 78 weeks for relapses. Twenty-eight dichotomous and continuous variables were assessed at baseline and week 12, including phenotype, inflammatory markers, disease activity (PCDAI) and other markers. Clinical relapses defined as PCDAI >10 after remission were recorded using a relapse form. Logistic regression & risk modelling was performed. RESULTS: We enrolled 282 eligible patients of whom 178 (63.6%) patients achieved steroid free remission by week 12. Disease complications developed in 22/76(29%) of patients with relapse compared to 20/206 (9.7%) without relapse (P = 0.01). Multivariable analysis demonstrated that while variables from age/gender at diagnosis were not predictive, week 12 variables including PCDAI >5 (P = 0.02), CRP >20 mg/L (P = 0.02), and faecal calprotectin >400 µg/g (P = 0.03) as optimal cut-offs were associated with increased risk of relapse. A prediction model for patients in remission including gender, age, week 12 PCDAI, calprotectin and CRP had sensitivity 43%, specificity 92%, PPV 78%, NPV 71% for relapse. CONCLUSIONS: Early relapses were associated with a higher risk for disease complications at followup. Relapse prediction based on week 12 disease activity or inflammation is superior to prediction using data from diagnosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ziv-Baran T, Hussey S, Sladek M, et al. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease. Aliment Pharmacol Ther. 2018. PMID: 30450578. doi:10.1111/apt.15016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。